CD96 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	38 studies	34% ± 11%	Explore
CD8-positive, alpha-beta T cell	36 studies	38% ± 11%	Explore
T cell	32 studies	36% ± 13%	Explore
CD4-positive, alpha-beta T cell	30 studies	35% ± 13%	Explore
regulatory T cell	22 studies	28% ± 8%	Explore
mature NK T cell	20 studies	35% ± 13%	Explore
CD16-negative, CD56-bright natural killer cell, human	16 studies	42% ± 16%	Explore
gamma-delta T cell	16 studies	44% ± 16%	Explore
mucosal invariant T cell	15 studies	41% ± 13%	Explore
CD16-positive, CD56-dim natural killer cell, human	15 studies	33% ± 7%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	15 studies	27% ± 8%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	14 studies	36% ± 10%	Explore
CD8-positive, alpha-beta memory T cell	12 studies	46% ± 9%	Explore
effector memory CD8-positive, alpha-beta T cell	11 studies	40% ± 13%	Explore
CD4-positive, alpha-beta memory T cell	10 studies	34% ± 8%	Explore
innate lymphoid cell	8 studies	44% ± 14%	Explore
effector CD8-positive, alpha-beta T cell	7 studies	34% ± 9%	Explore
adipocyte	7 studies	33% ± 10%	Explore
effector CD4-positive, alpha-beta T cell	6 studies	38% ± 15%	Explore
effector memory CD4-positive, alpha-beta T cell	6 studies	31% ± 8%	Explore
exhausted T cell	5 studies	40% ± 5%	Explore
leukocyte	5 studies	39% ± 16%	Explore
CD4-positive helper T cell	5 studies	39% ± 18%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	5 studies	36% ± 9%	Explore
lymphocyte	4 studies	59% ± 13%	Explore
T follicular helper cell	4 studies	37% ± 3%	Explore
group 3 innate lymphoid cell	4 studies	56% ± 3%	Explore
T-helper 17 cell	4 studies	37% ± 17%	Explore
central memory CD8-positive, alpha-beta T cell	4 studies	36% ± 9%	Explore
intraepithelial lymphocyte	3 studies	46% ± 9%	Explore
T-helper 1 cell	3 studies	44% ± 10%	Explore
central memory CD4-positive, alpha-beta T cell	3 studies	28% ± 9%	Explore
double negative thymocyte	3 studies	43% ± 6%	Explore
CD4-positive, alpha-beta cytotoxic T cell	3 studies	31% ± 9%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	11 studies	21% ± 2%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	100%	754.08	578 / 578	85%	6.96	982 / 1155
thymus	100%	436.97	651 / 653	78%	9.00	472 / 605
breast	87%	198.03	399 / 459	65%	5.25	724 / 1118
stomach	88%	238.61	316 / 359	61%	4.59	175 / 286
bladder	67%	483.00	14 / 21	70%	6.45	352 / 504
prostate	91%	235.36	223 / 245	42%	1.83	211 / 502
uterus	70%	101.56	119 / 170	63%	4.57	288 / 459
kidney	55%	137.34	49 / 89	65%	4.86	586 / 901
intestine	68%	483.89	660 / 966	50%	2.90	266 / 527
esophagus	48%	80.59	694 / 1445	70%	4.33	129 / 183
liver	79%	120.14	179 / 226	28%	1.43	113 / 406
lymph node	0%	0	0 / 0	100%	22.11	29 / 29
spleen	100%	1741.77	241 / 241	0%	0	0 / 0
peripheral blood	98%	1949.33	915 / 929	0%	0	0 / 0
adipose	92%	275.29	1105 / 1204	0%	0	0 / 0
skin	33%	42.03	601 / 1809	56%	5.59	265 / 472
tonsil	0%	0	0 / 0	89%	9.12	40 / 45
pancreas	16%	18.50	53 / 328	66%	4.82	117 / 178
ovary	29%	40.48	53 / 180	35%	1.51	152 / 430
adrenal gland	40%	41.90	104 / 258	11%	0.40	25 / 230
blood vessel	49%	103.76	655 / 1335	0%	0	0 / 0
heart	18%	23.97	153 / 861	0%	0	0 / 0
eye	0%	0	0 / 0	13%	0.53	10 / 80
brain	6%	7.07	146 / 2642	3%	0.14	23 / 705
muscle	1%	1.67	12 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0032689	Biological process	negative regulation of type II interferon production
GO_0006955	Biological process	immune response
GO_0002728	Biological process	negative regulation of natural killer cell cytokine production
GO_0006954	Biological process	inflammatory response
GO_0007155	Biological process	cell adhesion
GO_0032496	Biological process	response to lipopolysaccharide
GO_0007160	Biological process	cell-matrix adhesion
GO_0005737	Cellular component	cytoplasm
GO_0005886	Cellular component	plasma membrane

IV. Literature review

[source]

Gene name	CD96
Protein name	Alternative protein CD96 CD96 antigen, isoform CRA_b (CD96 molecule) (CD96 protein) T-cell surface protein tactile (Cell surface antigen CD96) (T cell-activated increased late expression protein) (CD antigen CD96) CD96 molecule
Synonyms	hCG_26934
Description	FUNCTION: May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation.
Accessions	H7C4F0 Q8WUE2 F8WDV3 ENST00000460744.1 ENST00000465428.1 U3KPT0 ENST00000488054.1 ENST00000494798.1 P40200 ENST00000283285.10 [P40200-1] E9PEJ1 ENST00000352690.9 [P40200-2] ENST00000438817.6 L8EAH0

CD96 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review